Complete Genomics Cuts Wages, Other Costs as it Seeks to Close Series D Financing Round

The company is in the late stages of closing a Series D investment, but due to the slowdown of the capital markets in recent months, "it has taken us longer than anticipated to close," a company official said.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.